September 2023 in “Forum Dermatologicum” This source discusses androgenetic alopecia, noting that male patients may transition from topical minoxidil to its systemic form or from finasteride to dutasteride for potentially better results, while female patients might require extensive lab testing to identify hyperandrogenism due to environmental triggers.
This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.
1 citations
,
November 2022 in “Aaps Pharmscitech” 
October 2022 in “Journal of Kermanshah University of Medical Sciences” The researchers reported that caprylic acid effectively enhances the permeability and diffusion of minoxidil through rat skin compared to other penetration enhancers.
1 citations
,
August 2022 in “Journal of Dermatological Treatment” In this study, the authors reported that oral dutasteride at 0.5 mg/day showed a probable greater efficacy in treating male androgenetic alopecia compared to finasteride and minoxidil, but it may cause sexual dysfunction and neuropsychiatric side effects.
12 citations
,
February 2022 in “Acta Biomaterialia” In this study, researchers found that dissolving microneedles made with hyaluronic acid enhanced the effectiveness of minoxidil in reducing hair loss and promoting hair growth in alopecia-affected mice more effectively than topical minoxidil alone, while using only 10% of the drug amount.
16 citations
,
June 2021 in “Journal of Dermatological Treatment” This study reported that while topical minoxidil exhibits hair regrowth in androgenetic alopecia, oral minoxidil 5 mg/day was more effective than topical forms after six months, with low doses also potentially effective for women and other hair loss types.
19 citations
,
July 2020 in “Journal of drug delivery science and technology” This study found that nano-sized minoxidil formulations significantly increased skin penetration and follicular drug delivery for alopecia areata treatment, compared to conventional ethanol-based solutions, and demonstrated effective controlled release over six hours.
34 citations
,
January 2020 in “Expert opinion on drug delivery” This review discusses various novel drug delivery approaches to enhance scalp drug penetration for alopecia treatment but reports no new clinical results.
15 citations
,
November 2019 in “Cutaneous and Ocular Toxicology” This study investigated a liposomal hydrogel system for delivering minoxidil and tretinoin to treat androgenic alopecia, finding that the system enhanced skin permeation of minoxidil while retaining tretinoin on the skin and was non-irritating in animal tests, suggesting its potential effectiveness.
27 citations
,
September 2018 in “Medicines” This study reported that oleic acid-based nanovesicles improve follicular delivery and reduce side effects of minoxidil compared to traditional MXD lotions.
178 citations
,
April 2017 in “Journal of The American Academy of Dermatology” This systematic review and meta-analysis found that minoxidil, finasteride, and low-level laser light therapy significantly improve hair growth in men with androgenetic alopecia, while minoxidil is also effective for women, compared to placebo.
16 citations
,
March 2017 in “Journal of inclusion phenomena and macrocyclic chemistry” This study found that using 2-hydroxypropyl-ß-cyclodextrin (HP-ß-CD) to encapsulate minoxidil can create a stable aqueous solution, potentially replacing the need for organic solvents in topical treatments for androgenic alopecia.
110 citations
,
August 2016 in “Drugs” Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.
77 citations
,
January 2015 in “International Journal of Biological Macromolecules” This study developed minoxidil sulphate-loaded chitosan nanoparticles that doubled drug delivery to hair follicles in vitro compared to a control solution, suggesting potential for improved alopecia treatment.
94 citations
,
September 2014 in “Therapeutic Delivery” This review describes recent advances in using nanoparticles for drug delivery to hair follicles, with potential applications in treating skin diseases such as alopecia and acne, but reports no new findings.
1 citations
,
September 2013 in “Elsevier eBooks” This review discusses factors affecting hair aging, such as inflammation and UV exposure, and examines potential anti-aging benefits of antioxidants and nutraceuticals for hair, but reports no new clinical results.
46 citations
,
September 2010 in “Southern Medical Journal” This review discusses low-level light therapy for androgenetic alopecia and female pattern hair loss, noting minimal clinical evidence on its efficacy and the need for more controlled studies.
85 citations
,
January 2007 in “Journal of Drug Targeting” This study found that liposomal formulations improved minoxidil delivery to skin layers compared to niosomes and a control solution, suggesting enhanced potential for topical hair loss treatment.
370 citations
,
September 1999 in “The New England Journal of Medicine” This article discusses the treatment of androgenetic alopecia and alopecia areata with finasteride and minoxidil but reports no new clinical results.
192 citations
,
March 1998 in “British Journal of Dermatology” This study found that minoxidil significantly increases VEGF mRNA and protein expression in dermal papilla cells, suggesting a role in enhancing hair follicle vascularization in androgenetic alopecia.
